Abstract: The present invention relates to new polynucleotides derived from the nucleotide sequence of the IFN?-17 gene comprising new SNPs, and new polypeptides derived from the natural wild-type IFN?-17 protein comprising at least one mutation caused by at least one SNP of the invention, as well as their therapeutic uses.

Abstract: Polynucleotides and polypeptides derived from the nucleotide sequence of the IFN?-21 gene comprising SNPs, and their therapeutic uses.

Abstract: Polynucleotides and polypeptides derived from the nucleotide sequence of the IFN?-21 gene comprising SNPs, and their therapeutic uses.

Abstract: The present invention relates to new polynucleotides derived from the nucleotide sequence of the IFN?-7 gene comprising new SNPs, and new polypeptides derived from the wild-type IFN?-7 protein comprising at least one mutation caused by at least one SNP of the invention as well as their therapeutic uses.

Abstract: The present invention relates to new polynucleotides derived from the nucleotide sequence of the IFN?-17 gene comprising new SNPs, and new polypeptides derived from the natural wild-type IFN?-17 protein comprising at least one mutation caused by at least one SNP of the invention, as well as their therapeutic uses.

Abstract: The present invention relates to new polynucleotides derived from the nucleotide sequence of the IFN?-5 gene comprising new SNPs, and new polypeptides derived from the natural wild-type IFN?-5 protein comprising at least one mutation caused by at least one SNP of the invention as well as their therapeutic uses.

Abstract: The present invention relates to new polynucleotides deriving from the nucleotide sequence of the EPO gene and comprising new SNPs, new polypeptides derived from the natural EPO protein and comprising at least one mutation caused by the SNPs of the invention as well as their therapeutic uses.

Abstract: The present invention relates to new polynucleotides deriving from the nucleotide sequence of the EPO gene and comprising new SNPs, new polypeptides derived from the natural EPO protein and comprising at least one mutation caused by the SNPs of the invention as well as their therapeutic uses.

Abstract: Methods for identifying and providing new therapeutic agent(s) by selecting at least one polypeptide encoded by a natural allelic variant of one preselected gene having a therapeutic potential; determining the therapeutic index of the selected polypeptide(s) and retaining as therapeutic agent(s) those polypeptide(s) whose therapeutic index is higher than that of a reference agent.

Abstract: The present invention relates to new polynucleotides derived from the nucleotide sequence of the IFN&agr;-14 gene comprising new SNPs, and new polypeptides derived from the natural wild-type IFN&agr;-14 protein comprising at least one mutation caused by at least one SNP of the invention as well as their therapeutic uses.

Abstract: The present invention relates to new polynucleotides derived from the nucleotide sequence of the IFN&agr;-5 gene comprising new SNPs, and new polypeptides derived from the natural wild-type IFN&agr;-5 protein comprising at least one mutation caused by at least one SNP of the invention as well as their therapeutic uses.

Abstract: Polynucleotides and polypeptides derived from the nucleotide sequence of the IFN&agr;-21 gene comprising SNPs, and their therapeutic uses.

Abstract: The present invention relates to new polynucleotides derived from the nucleotide sequence of the IFN&agr;-7 gene comprising new SNPs, and new polypeptides derived from the wild-type IFN&agr;-7 protein comprising at least one mutation caused by at least one SNP of the invention as well as their therapeutic uses.

Abstract: The present invention relates to new polynucleotides derived from the nucleotide sequence of the IFN&agr;-17 gene comprising new SNPs, and new polypeptides derived from the natural wild-type IFN&agr;-17 protein comprising at least one mutation caused by at least one SNP of the invention, as well as their therapeutic uses.

Abstract: Methods for identifying and providing new therapeutic agent(s) by selecting at least one polypeptide encoded by a natural allelic variant of one preselected gene having a therapeutic potential; determining the therapeutic index of the selected polypeptide(s) and retaining as therapeutic agent(s) those polypeptide(s) whose therapeutic index is higher than that of a reference agent.

Abstract: The present invention relates to new polynucleotides deriving from the nucleotide sequence of the EPO gene and comprising new SNPs, new polypeptides derived from the natural EPO protein and comprising at least one mutation caused by the SNPs of the invention as well as their therapeutic uses.

Abstract: The present invention relates to new polynucleotides derived from the nucleotide sequence of the IFN&agr;-2 gene and comprising new SNPs, and new polypeptides derived from the natural wild-type protein IFN&agr;-2 and comprising mutations caused by the SNPs of the invention, as well as their therapeutic uses.

Abstract: The present invention concerns a method for determining at least one functional SNP in a gene, comprising preselecting a candidate gene, providing a sample population comprising a significant number of individuals chosen substantially at random from the general population, isolating from each individual of the sample population at least one fragment of the nucleotide sequence of the preselected candidate gene, identifying at least one SNP in at least one fragment and determining the functionality of said SNP(s). The present invention also concerns applications of this method.